Armored Likho BusySnake Stealer, a Python-based infostealer first disclosed by Kaspersky, is actively targeting government ...

The AI-assisted editor now works alongside the platform's MCP server and interactive documentation, giving developers plain-language code generation, debugging, and reference lookup across a single ...

Modern business intelligence demands speed, and utilizing AI tools for Excel is the ultimate way to hyper-charge your data workflows this year.

Jupyter Notebook is a tool to run and write Python code easily, showing results right away, and allowing you to combine code, charts, notes, and files in one place. You can start Jupyter Notebook ...

On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...

A boring setting with huge payoff.

YouTube content creation often feels like a guessing game, but a new strategy empowers creators to use ChatGPT for data-driven success. The AI transforms instinct into evidence by analyzing competitor ...

EXCLUSIVE: Veteran literary scout Philippa Donovan wants to reverse engineer the books-to-screen market through her new business, Two Script Studio. The operation will create ‘reverse adaptations‘ to ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...